

# Prospective study evaluating ctDNA as a biomarker for treatment response in head and neck squamous cell carcinoma\*

Published: 12-04-2018

Last updated: 10-04-2024

To assess the kinetics of ctDNA in blood and saliva before, during and after definitive radiotherapy for HNSCC and to determine the prognostic value of ctDNA as predictor for treatment response in respect to conventional imaging.

<b>Ethical review</b>	Approved WMO
<b>Status</b>	Recruitment stopped
<b>Health condition type</b>	Miscellaneous and site unspecified neoplasms malignant and unspecified
<b>Study type</b>	Observational invasive

## Summary

### ID

NL-OMON46578

### Source

ToetsingOnline

### Brief title

PECAN

### Condition

- Miscellaneous and site unspecified neoplasms malignant and unspecified

### Synonym

Head and neck cancer

### Research involving

Human

### Sponsors and support

**Primary sponsor:** Antoni van Leeuwenhoek Ziekenhuis

**Source(s) of monetary or material Support:** KWF + RT research

## Intervention

**Keyword:** Biomarker, ctDNA, Head and neck cancer, Radiotherapy

## Outcome measures

### Primary outcome

To validate ctDNA after treatment as a predictor for the presence of residual disease and for the early detection of tumour recurrence.

### Secondary outcome

1. The prognostic value of ctDNA during treatment as a biomarker for treatment response.
2. Timing and accuracy of ctDNA as a predictor for recurrence in comparison to conventional imaging.
3. The correlation of traceable mutations found in blood / saliva in comparison to mutations found in tissue biopsies, as a parameter for tumor heterogeneity.
4. The tumours\* genomic status and epigenetic evolution over time under pressure of radiotherapy.
5. Sensitivity and specificity of ctDNA in blood compared to saliva.
6. The correlation between ctDNA before treatment and other clinical/biological parameters in the prediction of disease recurrence.

## Study description

### Background summary

Tumours continually shed DNA into the circulation, where it can be accessed. This circulating tumour DNA (ctDNA) directly reflects tumour burden and has great potential to be a sensitive biomarker for treatment recurrence. These \*liquid biopsies\* could give a more real-time picture of the genomic status and

evolution of a tumor and can be easily assessed for measurement of different biomarkers. However, in head and neck squamous cell carcinoma (HNSCC) patients treated with definitive radiotherapy, data regarding ctDNA kinetics and its correlation with outcome are scarce. A new or additional tool for response evaluation next to or instead of conventional imaging after treatment would be beneficial to detect recurrences in an earlier stage, thereby increasing the chances of success of salvage therapy. More importantly, an early response parameter during treatment could help to identify patients that have a good treatment response and might benefit from treatment adaptation. With this study, we aim to reveal ctDNA as an effective tool for future dose (de)-escalation trials in HNSCC.

### **Study objective**

To assess the kinetics of ctDNA in blood and saliva before, during and after definitive radiotherapy for HNSCC and to determine the prognostic value of ctDNA as predictor for treatment response in respect to conventional imaging.

### **Study design**

Prospective non-randomized observational study.

### **Study burden and risks**

Blood and saliva will be collected at regularly planned outpatient visits. This will be once before start of treatment, at 6-7 different moments during treatment and at five moments after end of treatment (38ml each). Tumor and germline DNA will be analyzed using sequencing techniques. Therefore, there is a small possibility of detection of unsolicited findings, i.e. germline DNA variants that confer an increased risk of developing malignancies or other diseases both for the patient and his/her family. In total, 3 extra conventional CT scans or MRI scans will be performed during follow up. These extra scans will be accompanied by (an acceptable amount of) radiation burden. The possible advantages of these extra scans will be very stringent follow up, with the possibility of more early and adequate therapeutic salvage treatment.

## **Contacts**

### **Public**

Antoni van Leeuwenhoek Ziekenhuis

Plesmanlaan 121  
AMSTERDAM 1066CX  
NL

## Scientific

Antoni van Leeuwenhoek Ziekenhuis

Plesmanlaan 121  
AMSTERDAM 1066CX  
NL

## Trial sites

### Listed location countries

Netherlands

## Eligibility criteria

### Age

Adults (18-64 years)

Elderly (65 years and older)

### Inclusion criteria

- $\geq 18$  years of age
- Stage II-IV carcinoma of the larynx, hypopharynx, oral cavity or HPV negative oropharynx, or stage II-III HPV positive oropharyngeal carcinoma, according to the American Joint Committee on Cancer (AJCC) staging manual 8th edition
- Indication for curative radiotherapy with or without concurrent radiosensitizer
- WHO performance status 0-2
- signed written informed consent

### Exclusion criteria

- Metastatic disease
- Radiotherapy with palliative intent
- Diagnosis of any other malignancy within 5 years prior to start of treatment except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix, or low-grade (Gleason 6 or below) prostate cancer on surveillance with no plans for treatment intervention (e.g. surgery, radiation or castration).

## Study design

### Design

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Diagnostic

### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 14-08-2018

Enrollment: 70

Type: Actual

## Ethics review

Approved WMO

Date: 12-04-2018

Application type: First submission

Review commission: METC NedMec

Approved WMO

Date: 28-06-2019

Application type: Amendment

Review commission: METC NedMec

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

### Register

CCMO

### ID

NL64571.031.18